Some words from management would be helpful.
I hope we are not looking at a RAK situation.
Printable View
Some words from management would be helpful.
I hope we are not looking at a RAK situation.
Ah but they needed to raise some cash then.
...being caused by all the sheep following that squiggly line.
We are nearly two months on from the sales figures and there has been no further advice or evidence as to the subsequent or current sales - except somebody (deliberate vagueness here!!) mentioning there were apparently 12 sales people on the ground at the moment. I would like to think they are at least earning their keep, but knowing sales people - they'll be chasing as many sales as they can get.
Will be interesting to see who is mopping up these shares and how big the shareholder list will be next time it is published. I will review my holding after I have heard what the Board has to say at the AGM - and not before.
One last bit - I do my own research like everyone says to do - but I try not to influence other holders transactions on the basis of my own opinions. If I lose, I lose - but it's all down to me. I could not stomach being part of a losing sharemarket transaction - based on someone else's research or opinion. Thanks to the sheep...I'll be looking to increase my holding shortly...but a bit more wool to shear first though!
Why do you all seem so gobsmacked. Look at what is happening in the world... since March especially.
It is a complex sector and tech to research too isn’t Dentie, there are no analysts yet, but coming soon, and the thing about market correlations is that they just serve to create distortions in individual stock valuations. A transfer of wealth over time from the fickle to the patient.
Within the NZX SciTech, I’ve XRO still well overvalued at these levels, but ATM and PEB as being considerably undervalued. At some point the current pulling the others under will release and stock picking will prevail at discounted prices.
As with ATM, the funds are probably mopping nicely up from small holders, we’ve not seen any significant SSH’s from the major PEB shareholders, and that just serves to lower liquidity for those scrambling to buy back in when they do.
That's a bit harsh. The announcements were made because they had signed, what they considered, material contracts. Further to that, they raised the cash at low price, compared to the share price at that point in time, and in hind sight, they would have waited a few days before announcing the capital raising as they probably could have raised twice as much cash for the same amount of shares (actually, they were limited to $15k per person so it would have been the same amount of cash for less dilution).
Last time I checked mining companies were not included within the NZX SciTech.
I’m just suggesting that not all companies are valued the same when these short term type correlations occur, some will be undervalued when the dominant stock within the sector drags those stocks down, yes like PEB, ATM and others within the sector. I only research and value a few within the SciTech, I have DIL and CVT as undervalued also.
I don’t believe anyone takes advice from this forum and act solely based upon it. And, as Dentie wisely reminds us, we may share fundamental information but must do our own research, and thus make our own judgements as to investing or otherwise.
Ha, I'm not sure I do with that one Moosie, but I an a subscriber to "the trend is your friend until it's not", and I do like WB as he often says it best for me “price is what you pay, value is what you get” and one of my favourite of his quotes “if past history was all there is to the game, the richest people would be librarians”.
I posted a link to an abstract to this article a while ago, but here is a link to the full version:
Review article Sapre et al "gene based urinary biomarkers for bladder cancer"
http://www.urologiconcology.org/arti...text#copyright
Excerpts:
There is a pressing need for an accurate noninvasive test to assist diagnosis and surveillance of BCa. Urine is in direct contact with BCa cells, and hence is an ideal source for investigation of noninvasive biomarkers of BCa.
....
Cytology, the only urinary test that currently aids cystoscopy in routine follow-up of patients has high interobserver variability and poor sensitivity especially for low-grade tumors [4]. Several studies now support the cost-effectiveness of incorporating noninvasive urinary biomarkers in the surveillance of BCa [2]. An ideal noninvasive test for BCa should give a bedside result, be cheap, easy to use, reliable and accurate, and not be affected by inflammation and infection. Most importantly, it must have a high negative predictive value (sensitivity) to avoid missing tumors.
....
There are several protein- and cell-based commercial and investigational markers that have been the subject of much research, such as nuclear matrix protein 22, bladder tumor antigen, ImmunoCyt, BLCA, and hyaluronic acid/hyaluronidase, which have been extensively reviewed previously and are not discussed further here. Table 1 summarizes the current commercial and investigational urinary biomarkers in BCa. However, the performance of such cell- and protein-based tests has been too inadequate to incorporate them into routine clinical practice, primarily because they are affected by other bladder conditions such as infection, inflammation, and intravesical therapy, and this has given a way for gene-based biomarker testing in more recent times.
....
The most promising new biomarker and the closest to clinical translation is the uRNA2 assay (Cxbladder; Pacific Edge, New Zealand)
....
The lack of clinical benefit of protein- and cell-based urinary biomarkers and the emergence of high-throughput genomic platforms have given way to pursuit of gene-based profiling of biomarkers. However, the majority of these studies remain in the discovery phase, and what is now needed for clinical translation of these markers is multicenter prospective validation studies in large clinical settings with adequate scientific and statistical rigor.